Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of intravitreal pegcetacoplan in Japanese participants with geographic atrophy secondary to age-related macular degeneration
jRCT2071260009Phase 3Recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- May 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in age-related macular degeneration (AMD), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious treatment-emergent adverse events. Started May 2026; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCT2071260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260009.